Ulcerative colitis: treatment with biologicals
| dc.creator | Fabio Vieira Teixeira | |
| dc.creator | Sender Jankiel Miszputen | |
| dc.creator | Eduardo Garcia Vilela | |
| dc.creator | Aderson Omar Mourão Cintra Damião | |
| dc.creator | Andrea Vieira | |
| dc.creator | Idblan Carvalho de Albuquerque | |
| dc.creator | José Miguel Luz Parente | |
| dc.creator | Júlio Maria Fonseca Chebli | |
| dc.creator | Orlando Ambrogini Junior | |
| dc.creator | Rogerio Saad Hossne | |
| dc.date.accessioned | 2024-10-03T20:09:15Z | |
| dc.date.accessioned | 2025-09-09T00:58:07Z | |
| dc.date.available | 2024-10-03T20:09:15Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | O tratamento farmacológico da retocolite ulcerativa (RU) visa reduzir o processo inflamatório e manter a remissão dos sintomas1,2. Apesar do progresso terapêutico, as opções de tratamento para RU ativa moderada a grave permanecem limitadas, devido ao controle parcial obtido com terapia convencional (sulfasalazina, aminossalicilatos, glicocorticoides e imunossupressores) em uma proporção substancial de pacientes, e a existência de eventos adversos. Atualmente, os medicamentos de escolha para a abordagem terapêutica desses pacientes são os agentes anti-fator de necrose tumoral alfa (anti-TNF-α), infliximabe, adalimumabe e golimumabe, e mais recentemente, o agente anti-integrina (vedolizumabe) antagonista seletivo desta molécula de adesão no intestino | |
| dc.format.mimetype | ||
| dc.identifier.doi | https://doi.org/10.1590/1806-9282.65.4.547 | |
| dc.identifier.issn | 18069282 | |
| dc.identifier.uri | https://hdl.handle.net/1843/77188 | |
| dc.language | eng | |
| dc.publisher | Universidade Federal de Minas Gerais | |
| dc.relation.ispartof | Revista da Associação Médica Brasileira | |
| dc.rights | Acesso Aberto | |
| dc.subject | Colite Ulcerativa | |
| dc.subject | Tratamento Farmacológico | |
| dc.subject.other | Colitis, Ulcerative | |
| dc.subject.other | Drug Therapy | |
| dc.title | Ulcerative colitis: treatment with biologicals | |
| dc.title.alternative | Colite ulcerativa: tratamento com biológicos | |
| dc.type | Artigo de periódico | |
| local.citation.epage | 553 | |
| local.citation.issue | 4 | |
| local.citation.spage | 547 | |
| local.citation.volume | 65 | |
| local.description.resumo | The pharmacological treatment of ulcerative colitis (UC) aims to reduce the inflammatory process and maintain remission of symptoms1,2. Despite the therapeutic progress, treatment options for moderate to severe active UC remain limited, due to the partial control obtained with conventional therapy (sulfasalazine, aminosalicylates, glycyclorticoids and immunosuppressants) in a substantial proportion of patients, and the existence of adverse events. Currently, the drugs of choice for the therapeutic approach of these patients are anti-tumor necrosis factor alpha (anti-TNF-α) agents, infliximab, adalimumab, and golimumab, and more recently, the anti-integrin agent (vedolizumab) selective antagonist of this adhesion molecule in the intestine | |
| local.publisher.country | Brasil | |
| local.publisher.department | MED - DEPARTAMENTO DE CLÍNICA MÉDICA | |
| local.publisher.initials | UFMG | |
| local.url.externa | https://www.scielo.br/j/ramb/a/YyrcYf6zSFnwGhN4tDfWvDL/?lang=en |